CTRI/2018/07/014788尚未招募未知
To compare the efficacy and safety of dry powder inhaler of formoterol/glycopyrronium with dry powder inhaler of formoterol/budesonide in fixed dose combination in patients of chronic obstructive pulmonary disease(COPD).
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Age >19years
- •Baseline fev1 <80%of predicted normal and a baseline FEV1/FVC ratio >70%
- •Signed and dated written informed consent obtained prior to participation
排除标准
- •known case of respiratory disierder other than COPD
- •known case of significant inflammatory disease other than COPD
- •known to be severely alpha 1 antitrypsin deficient
- •known hypersensitivity to study medication or components
- •having undergone lung surgery
- •having or have had malignancy in last 5 years
- •serious uncontrolled disease likely to interfere with the study
- •pregnant and lactating females
- •known case of HIV or HbsAG or Anti HCV positivity
- •immunocompromised
- •with severe cardiovascular disease
研究者
相似试验
已完成
3 期
A clinical trial to study and compare the effects two dry powder inhaler devices,test and reference, containing salmeterol 25mcg and fluticasone propionate 250mcg with salmeterol 50mcg and fluticasone propionate 500mcg in patients with asthma.CTRI/2008/091/000302Sun Pharma Advanced Research Company Ltd113
已完成
不适用
Investigation of the applicability of dry powder inhalation in school childrecystic fibrosis10024970mucoviscidosisNL-OMON37634Rijksuniversiteit Groningen104
已完成
不适用
Investigation of the applicability of dry powder inhalation in children with cystic fibrosis10024970cystic fibrosismucoviscidosisNL-OMON40571Rijksuniversiteit Groningen40
已完成
不适用
Investigation of the applicability of dry powder inhalation in patients with Parkinson*s disease.Parkinsons diseaseParkinson10028037NL-OMON38957Rijksuniversiteit Groningen15
已完成
不适用
Dry powder inhalation in patients with Parkinson’s disease.Ability of a Parkinson’s patient to use the inhaler correctly during off periods.NL-OMON24879Department of Pharmaceutical Technology and Biopharmacy, Faculty of Mathematics and Natural Sciences, University of Groningen15